Patient baseline characteristic and PE characteristics (n = 150)
| Characteristic . | No underlying conditions, n = 58∗ . | Underlying conditions present, n = 92∗ . | P value† . |
|---|---|---|---|
| Age, y | 16 (15, 17) | 16 (14, 17) | .08 |
| Male sex | 21 (36%) | 52 (57%) | .02 |
| BMI percentile | 77 (54, 96) | 85 (56, 96) | .61 |
| Symptomatic PE | 52 (90%) | 69 (76%) | .04 |
| Thrombophilia | .006 | ||
| Major | 11 (20%) | 23 (32%) | |
| Minor | 12 (22%) | 3 (4%) | |
| None | 31 (57%) | 47 (64%) | |
| Oral contraceptive use | 29 (78%) | 12 (30%) | <.001 |
| Anatomic variations | 5 (9%) | 4 (4%) | .31 |
| Trauma/surgery | 11 (19%) | 13 (14%) | .43 |
| Concomitant DVT | 27 (52%) | 56 (65%) | .13 |
| Hospital-acquired PE | 17 (29%) | 58 (63%) | <.001 |
| Massive/submassive PE at presentation | 8 (14%) | 17 (19%) | .44 |
| Treatment | |||
| Anticoagulation + thrombolysis/thrombectomy | 11 (19%) | 12 (13%) | .15 |
| Anticoagulation | 47 (81%) | 75 (82%) | |
| None | 0 (0%) | 5 (5%) |
| Characteristic . | No underlying conditions, n = 58∗ . | Underlying conditions present, n = 92∗ . | P value† . |
|---|---|---|---|
| Age, y | 16 (15, 17) | 16 (14, 17) | .08 |
| Male sex | 21 (36%) | 52 (57%) | .02 |
| BMI percentile | 77 (54, 96) | 85 (56, 96) | .61 |
| Symptomatic PE | 52 (90%) | 69 (76%) | .04 |
| Thrombophilia | .006 | ||
| Major | 11 (20%) | 23 (32%) | |
| Minor | 12 (22%) | 3 (4%) | |
| None | 31 (57%) | 47 (64%) | |
| Oral contraceptive use | 29 (78%) | 12 (30%) | <.001 |
| Anatomic variations | 5 (9%) | 4 (4%) | .31 |
| Trauma/surgery | 11 (19%) | 13 (14%) | .43 |
| Concomitant DVT | 27 (52%) | 56 (65%) | .13 |
| Hospital-acquired PE | 17 (29%) | 58 (63%) | <.001 |
| Massive/submassive PE at presentation | 8 (14%) | 17 (19%) | .44 |
| Treatment | |||
| Anticoagulation + thrombolysis/thrombectomy | 11 (19%) | 12 (13%) | .15 |
| Anticoagulation | 47 (81%) | 75 (82%) | |
| None | 0 (0%) | 5 (5%) |